Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Lenalidomide

10 mg daily given for 12 months

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00632359 - Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease | Biotech Hunter | Biotech Hunter